APM
CNTX icon

Avidity Partners Management’s Context Therapeutics CNTX Stock Holding History

Avidity Partners Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.9M Buy
9,996,534
+4,491,679
+82% +$10.5M 2.66% 7
2025
Q4 		$8.09M Sell
5,504,855
-3,477,000
-39% -$4.06M 2.33% 11
2025
Q3 		$8.7M Buy
8,981,855
+1,504,600
+20% +$1.22M 1.98% 14
2025
Q2 		$4.9M Buy
7,477,255
+55
+0% +$40 0.98% 34
2025
Q1 		$4.58M Hold
7,477,200
– – 0.87% 43
2024
Q4 		$7.85M Buy
7,477,200
+60,045
+0.8% +$104K 0.77% 47
2024
Q3 		$14.5M Sell
7,417,155
-2,200
-0% -$4.88K 0.74% 51
2024
Q2 		$14.9M Buy
+7,419,355
New +$12.8M 0.63% 57

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Avidity Partners Management's CNTX Position: Q1 2026 in Review

Avidity Partners Management increased its Context Therapeutics (CNTX) stake by 82% in Q1 2026, buying an estimated $10.5M and bringing the position to 9,996,534 shares worth $24.9M. The position accounts for 2.66% of the portfolio, ranked #7.

Avidity Partners Management first reported a position in CNTX in Q2 2024 and has held it in 8 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Avidity Partners Management held 9,996,534 shares of Context Therapeutics worth $24.9M as of Q1 2026.
  • Avidity Partners Management bought 4,491,679 Context Therapeutics shares in Q1 2026, an estimated $10.5M.
  • Context Therapeutics made up 2.66% of Avidity Partners Management's portfolio in Q1 2026, its #7 holding.
  • Avidity Partners Management first reported a position in Context Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.